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Abstract
Background: Human oesophageal carcinoma is considered to be one of the most aggressive malignancies and
has a very poor prognosis. The incidence of oesophageal cancer shows a gender bias and is higher in males
compared with females, the ratio between males and females varying from 3:1 to 7:1. This sex ratio is not entirely
attributable to differences in the prevalence of known risk factors between the sexes. The potential role of
oestrogen receptors (ER) in oesophageal cancer has been debated for several years but the significance of the
receptors in this cancer remains unknown. Most of the work has been based on immunohistochemistry and has
not been validated with other available techniques. The inconsistencies in the published literature on the link
between ER expression and oesophageal cancer warrant a thorough evaluation of the potential role of ERs in this
malignancy. Even the expression of the two ER isoforms, ERa and ERb, and its implications for outcome of
treatments in histological subtypes of oesophageal tumours is ill defined. The aim of this article is to provide
updated information from the available literature on the current status of ER expression in oesophageal cancer and
to discuss its potential therapeutic role.
Methods and Results: We performed a comprehensive literature search and analysed the results regarding ER
expression in oesophageal tumours with special emphasis on expression of different oestrogen receptors and the
role of sex hormones in oesophageal cancer. This article also focuses on the significance of the two main ER
subtypes and mechanisms underlying the presumed male predominance of this disease.
Conclusion: We postulate that differential oestrogen receptor status may be considered a biomarker of poor
clinical outcome based on tissue dedifferentiation or advanced stage of the disease. Further, if we can establish the
importance of oestrogen and its receptors in the context of oesophageal cancer, then this may lead to a new
future direction in the management of this malignancy.
Introduction
Human oesophageal carcinoma is the eighth most com-
mon type of malignancy in the world [1], with approxi-
mately half a million people diagnosed annually
worldwide [2]. Over the last three decades, the incidence
of oesophageal cancer in many parts of the world has
risen significantly [3-7]. The prevalence of the two main
histological subtypes of oesophageal cancer, adenocarci-
noma (AC) and squamous cell carcinoma (SCC) varies
depending upon geographical location [8]. The AC is
common in Europe and Australia [9] followed by the
USA [8,9], while SCC predominates in Asian countries
especially in the far East[10]. The incidence of
oesophageal AC in the western world has risen rapidly
over several years [11-13] whilst that of SCC has
decreased[8], although increasing trends have been
observed in Denmark and the Netherlands among men
[14]. Carcinogens including dioxins, nitrosamines and
polycyclic aliphatic hydrocarbons present in tobacco,
processed meats and fried foods along with alcohol con-
sumption and gastrooesophageal reflux disease and
others have all been identified as risk factors for oeso-
phageal cancer[15] although contribution of aetiological
factors varies amongst histological subtypes of the dis-
ease. Figures 1 and 2 depict the risk factors for AC and
SCC respectively.
Among the different treatment options, surgical resec-
tion is used most frequently to obtain locoregional con-
trol and long-term survival [16]. However, because of
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any medium, provided the original work is properly cited.early tumour recurrence and metastasis, the overall five
year survival after resection is around 35% [17,18]
The AC of the oesophagus is predominantly a male
disease with a male to female ratio of 6-8:1 [14]. It is
also reported that both the AC [19] and SCC [20] of the
oesophagus are more common in males than females
with a male to female ratio exceeding 3-6:1 or higher in
some studies [20-22]. Barrett’s oesophagus, identified as
a potential risk factor for AC, also occurs predominantly
in males with a male: female ratio ranging from 2:1 to
4:1 [23,24]. Lofdhal et al have suggested that the sex dif-
ference in oesophageal AC does not seem to be
explained by differences in risk factor profile of known
aetiological agents such as reflux, obesity and tobacco
consumption [25].
Badwe et al (1994) studied the impact of age and sex
on survival after curative resection for carcinoma of the
oesophagus with life stable analysis showing a signifi-
cantly better 5 year survival for women under 49 years
of age (35%, CI 24-48) compared with men of the same
age (16%.CI 8-27) (P < 0.008)[26]. The gender of the
patient was found to be the second most significant
determinant of survival (p = 0.002) after lymph node
metastasis. These results of better survival benefit for
women provides support for the hypothesis that the
endocrine milieu in premenopausal women may prevent
the micrometastases of the oesophageal malignancy and
the consequent improved prognosis for oesophageal
cancer [26].
A population-based study by Derakhshan et al, has sug-
gested that the increased incidence of oesophageal cancer
in females is age-related and occurs postmenopausally
[27]. Measuring and correlating systemic sex steroid hor-
mone levels and their interaction with their receptors in
pre- and postmenopausal women may help elucidate the
age-related incidence in postmenopausal females.
The observation that females appear to have a survival
benefit compared to males [28,29] has led us to consider
mechanisms through which oestrogens acting via the
oestrogen receptor (ER) are implicated in the gender bias
thus raising the possibility of using ER status as a positive
or negative biomarker of disease outcome. Our recent
work on oesophageal cancer has indicated overexpression
of immunoreactive oestrogen receptor beta (ERb)a s
compared to oestrogen receptor alpha (ERa)a n da n d r o -
gen receptors in oesophageal cancer[30] (Figure 3).
Oestrogen receptors (ER)
In addition to their well-documented roles in the repro-
ductive tract, diminished ovarian oestrogen levels are
Figure 1 Aetiological factors for oesophageal adenocarcinoma.
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Figure 2 Aetiological factors for oesophageal squamous cell cancer.
Rashid et al. World Journal of Surgical Oncology 2010, 8:9
http://www.wjso.com/content/8/1/9
Page 3 of 10implicated in the development of osteoporosis and the
raised risk of cardiovascular disease in postmenopausal
women [31]. The actions of oestrogens, a group of C-18
steroids, are mediated principally via ERa and ERb first
cloned from rat prostate [32]. This discovery led to a
reappraisal and new perspective on the significance of
the ER in health and disease. The ERa and ERb, isoforms
are respectively encoded by two distinct genes (ESR1 and
ESR2) located on chromosome 6q25.1 and chromosome
14q22-24[33,34]. The two receptors share common func-
tional domains with a conserved (95% sequence homol-
ogy) central DNA-binding domain thought to be
involved in receptor dimerisation [35] (Figure 4). The ER
also possesses two activation function domains AF1 and
AF2 [36] with the former interacting with non-ER tran-
scription factors while AF2 contains the ligand binding
domain (LBD) [37]. Interestingly, AF1 in ER-b lacks
functional activity [36]. Of the natural oestrogens that
include oestrone and oestriol, oestradiol-17b (E2)h a st h e
highest affinity for both ER subtypes.
The ER belongs to the NR3 steroid receptor class of
the nuclear receptor superfamily and consistent with the
mechanisms of action of this family, it operates via tran-
scriptional regulation to cause downstream changes in
gene expression. This follows dissociation of the intra-
cellular ER from chaperone proteins, principally heat
shock proteins (eg HSP90) on binding of ligand, thus
releasing the ER-complex for attachment to oestrogen
response elements located in the promoter region of tar-
get genes [31]. The recruitment of coregulators that
either activate or repress gene transcription ultimately
determines the cellular response. ER functions may also
be mediated by non-genomic mechanisms that are pre-
dominantly transduced at the membrane and are acute
in nature with the physiological response occurring
within minutes as opposed to hours [38].
Expression of ER and other sex hormone
receptors in oesophageal cancer
Conflicting data exist on the expression of sex steroid
receptors in oesophageal cancer and hence their role in
the progression of the disease. Lagergren et al., 1998
[21] suggested that in the absence of other known envir-
onmental risk factors with a sex distribution which is
Figure 4 Pathways of oestrogen action. The ERa/ERb is a simplified schematic of the ER. MAPK mitogen activated protein kinase, PKC protein
kinase C, PKA protein kinase A, cAMP 3’-5’ cyclic adenosine monophosphate, Ca
2+ intracellular calcium, DBD DNA binding domain, LBD ligand
binding domain.
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of adenocarcinoma, male predominance might be due to
hormonal factors. Either high oestrogen and/or proges-
terone levels, low testosterone or a combination of these
may be the reason why women are apparently protected
from developing oesophageal cancer. If the aforemen-
tioned presumption is correct, then any treatment that
increases oestrogen levels and/or decreases testosterone
levels may potentially reduce the risk of developing ade-
nocarcinoma of the oesophagus [21]. However this is a
rather simplistic notion when one considers the multi-
factorial influences and underlying cellular mechanisms
that shape development of this disease.
There is limited evidence on progesterone receptor
expression in oesophageal cancer although Kalayarasan
et al., have shown it is absent in both normal epithelial
mucosa and oesophageal tumours [39]. With respect to
the androgen receptor (AR), Tiffin et al., [40] demon-
strated focal staining of this receptor in only two of ten
patients [40] whilst Awan et al., [41] identified AR
expression in the stromal component of oesophageal
adenocarcinoma [41]. Nuclear and cytosolic AR expres-
sion in two newly established human oesophageal carci-
noma cell lines (ES-25C and ES-8C) has also been
shown [42]. Androgen receptors may be important med-
iators of oesophageal cancer as shown in studies where
oesophageal SCC cell lines underwent enhanced growth
when treated with testosterone in vitro studies [43,44].
Shinji Tanaka et al., are of the opinion that androgens
too may play a role in the regulation of gene expression
associated with malignant transformation [45].
In studies of the ER expression in oesophageal cancer,
Nozoe et al., [46] suggested an inverse relationship
between ERa and ERb, in oesophageal squamous cell
cancer [46]. Although Kalayarasan et al.,, investigating
the expression of ER between oesophageal cancer and
normal oesophageal mucosa reported no detectable
immunohistochemical expression for ERa,t h ea u t h o r s
propose a positive correlation of ERb status with tumour
dedifferentiation, type and stage [39]. Interestingly, AC
s h o w e dah i g h e rm e a ns c o r ef o rE R b expression as com-
pared with SCC. Furthermore, ERb positive immunoreac-
tivity in tumour cells increased with dedifferentiation and
increasing tumour stage in both types of oesophageal
cancer and has prompted suggestions that ERb status is a
potentially useful marker of worsening disease progres-
sion [39]. In contrast, to the findings of Kalayarasan et
al., [39] Tiffin et al., [40], identified mild to moderate
staining of ER in most of their oesophageal tissue sam-
ples but the authors did not discriminate between the ER
subtype detected [40]. Given the conflicting evidence on
the ERa and ERb expression in oesophageal cancer,
Table 1 summarises the studies performed to date. Cui et
al., [47] have also examined ER expression but patients
in this study had oesophagogastric carcinomas likely ori-
ginating from the stomach.
Table 1 Studies assessing the risk of oesophageal cancer in relation to oestrogen receptors.
No of
patients
M:F PR ER-a ER-b Histological
subtypes of OC
Source &
affinity of
ER AB
Significance/Dedifferentiation
Kalayarasan et al.,
(India, 2008)[39]
45 3:2
(SCC)
4:1
(AC)
0 0 45 AC (n = 15)
SCC (n = 30)
AC>SCC
Novacastra-
ERa- Clone
6F11-
ERb- Clone
EMR02-
ERb staining
increases with dedifferentiation
Boone J et al,
(Netherlands,2009)
[54]
108
(Tissue
Microarray)
0 0 100% s SCC Dako-
M7047
No staining found with ERa
Nozoe T et al.,
(Japan, 2007)[46]
73 10:1 ND 47 21 100% SCC Santa Cruz-
HC-20(a)
H-150(b)
ERa expression
-unfavourable independent
prognostic indicator
Tiffin et al.,
(UK,2003)[40]
20 1:1 ND ND ND ER= +ve
(n = 8 AC)
Dako-
NS
Oestrogen receptors are more
important than androgen receptors-
require further investigations
Wang L et al.,
(China,1991)[56]
48 19 Unknown Unknown Unknown Unknown Gender & grade of tumour were
influencing ER expression
Akgun et al.,
(USA,2002)[49]
31 ND ND NA 23 AC NS-
MYEB(b)
AC, BM show higher expression of
ERb
Liu et al., (USA,
2004)[55]
33 ND ND NA ERb 1 = 23/27
ERb 2 = 22/27
ERb 3 = 27/27
ERb5 = 27/27
ACC>Barrett’s
metaplasia
negative for
dysplasia
In house-
Human ER-b
(amino acids
1-12).
ERb subtypes are overexpressed in
oesophgael cancer as compared to
its precursor lesions
ND: Not determined; PR progesterone receptor; AB: antibody; AC: adenocarcinoma; BM: Barrett’s metaplasia; NS: not specified; OC: oesophageal cancer; NA: not
applicable
*Tiffin et al[40] (n = 20), Six patients with metaplasia also had positive ER staining
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oesophageal carcinoma cells mediated via sex hormone
receptors is influenced by circulating hormone levels
and can be manipulated by systemic oestradiol adminis-
tration [48]. The effectso fv a r i o u sd o s e so fE 2 on in
vitro growth of these cell lines has established that one
of the cell lines (ES-25C) showed significant inhibition
at concentrations of 10
-10 and 10
-12 mol/l compared
with the control, indicating a role for the oestrogen-ER
system in growth inhibition of ER+ oesophageal cancer
cell by oestradiol-17b [42,48]
In studies following the development of Barrett’st o
oesophageal cancer, it was found that of 31 patients
who underwent oesophagectomy, more than 50% (23/
31) were found to have positive staining for ER-b [49].
Among patients with high grade dysplasia,10 out of 11
(91%) showed positivity and this ratio was found to be 8
out of 11 (83%) in low grade dysplasia and 10 out of 15
in patients with Barrett’s metaplasia having no dysplasia.
The authors of the study conclude that premalignant
Barrett’s and oesophageal adenocarcinoma display posi-
tive ERb immunoreactivity in a significantly high pro-
portion [49]. Given the inconclusive data on studies of
the ER subtype expression in cancer, the poor specificity
of earlier antibodies against ERb has highlighted the
need to validate methods and reagents properly. This is
especially applicable to studies designed to produce
accurate and meaningful outcomes on which to base
future applications of ERb as a prognostic measure.
ERs and link with other cancers
Mounting evidence supports a role for the ER in halting
or promoting cancer progression. Most of our current
understanding on the biological significance of ERs in
tumourigenesis has emerged from studies of breast can-
cer and the relationship between the expression of ERa
and response to the nonsteroidal antioestrogen, tamoxi-
fen. Oestrogens and ERs also play a vital role in the
development or suppression of several other malignan-
cies classified into four main subgroups [50,51] most of
which express both ERa and ERb [50,51]. Specifically, in
the Women’s Health Initiative study in which a cohort
of 16,608 women were randomized into either a hor-
mone replacement therapy (HRT) group or a non-HRT
group [52], the risk of colorectal cancer was almost
halved in women receiving HRT. Similarly, the associa-
tion between HRT and risks of oesophageal and gastric
cancer was studied in a nested-case control study where
a total of 1619563 patients were identified from the
General Practitioners Research Database in the UK. The
conclusions of this latter study were that HRT leads to
a 50% reduction in the risk of gastric adenocarcinoma
but there was no relationship between HRT and oeso-
phageal adenocarcinoma [53]. However, only a relatively
small number of women with oesophageal cancer (n =
299) [53] were included which may have limited the
power of the study. In addition, the lack of such associa-
tion does not exclude more complex cellular and mole-
cular interactions that are not detectable in this sort of
clinical study.
Mechanisms underlying altered ER expression
and activity in oesophageal cancer and
therapeutic implications
Based on the available yet rather scarce literature on the
potential association of ER receptor expression with
oesophageal cancer [39,40,46,49,54-56], some of the
mechanisms underlying ER and E2 interactions in oeso-
phageal cancer are based on studies of other cancers in
which ERs have been implicated and are briefly dis-
cussed below:
Differential ERa and ERb expression and the ERa:
ERb ratio in cancer
In many cancers, ERa appears to be instrumental in
promoting cell proliferation. However, recent studies
have suggested that both mRNA and protein levels of
ERb may have greater significance in certain cancers. A
loss of ERb expression is observed in colorectal [57,58],
prostate [59] and breast [60] carcinoma that all express
high levels of ERb in normal tissues [60,61]. Decreased
ERb levels are associated with improved disease out-
comes and longer term disease-free survival in malig-
nant mesothelioma attributed to the antiproliferative
effects of ERb[62]. The beneficial effects of HRT in
colon cancer, which expresses very little ERa in normal
colon, are likely to be mediated by downregulation of
ERb [58]. Evidence supports a possible protective role
for ERb in prostate cancer where a loss of ERb expres-
sion accompanied the development of prostate cancer
[59]. Interestingly, the small number of cancers that
continued to express ERb were positively correlated
with a higher rate of relapse [59]. In malignant mesothe-
lioma, attenuated ERb expression appears to be an inde-
pendent indicator of improved prognosis and survival
[62]. Yet in tissues expressing both isoforms of the ER
at comparable levels, the growth inhibitory effects of
ERb are less obvious thought to be due to the lack of
AF1 ERb activity. ERb is known to bind to and suppress
ERa function [63,64] thereby demonstrating inverse bio-
logical activity.
Activation of ER-a and ER-b involves the formation of
dimers and as the two isoforms are coexpressed in many
cell types, receptors may exist as ERa (aa)o rE R b (bb)
homodimers or as an ERab (ab) heterodimer [65].
Homo- and heterodimerisation may also introduce
diversity of tissue and cell-specific functions.
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abundance of ERa:ERb, dominance of one ER dimer
over another and their roles in many of oestrogen’s
nonendocrine functions that likely contribute to disease
onset and severity.
Phosphorylation and ligand-independent
activation of ER
Gene transcription via ER may proceed indirectly with-
out binding of native ligand to oestrogen response ele-
ments involving instead protein-protein interactions.
The most prominent for ERa appear to be the tran-
scription factors, specificity protein (SP-1) and nuclear
factor kappa b (NFB), the proinflammatory transcrip-
tion factor. The activator protein-1 (AP-1) complex of
Jun/Fos hetero- or homodimers is a key regulator of cell
proliferation with one of the target genes identified as
cyclin D1. Depending on the whether ERa or ERb is
activated, the AP-1 complex acts in a reciprocal fashion
to stimulate or inhibit cell proliferation. Ligand-indepen-
dent activation may also determine the phosphorylation
status of ERa which occurs principally at serine residues
in the AF1 domain (Figure 4) [31]. Phosphorylation of
ER may also occur via a plethora of bioactive mediators
that include growth factors, cytokines and enzymes and
has been linked with hormone-independent growth, loss
of cell-cell adhesion and angiogenesis.
Proliferation and apoptosis
The mitogenic and growth-promoting actions of oestro-
gens in target tissues are well-established and are achieved
in part by increased transcription of cell-cycle genes via
ERa. However, in certain cancers where ERb is considered
protective, antiproliferative effects are achieved by cell
cycle growth arrest for example by down-regulation of the
cyclin D1 (CCND1) gene thereby preventing cellular pro-
gression from the G1 to S-phase of the cell cycle. ERb may
also inhibit gene transcription induced by ERa.T h e s e
lines of evidence have led to the suggestion that ERb acts
as a tumour suppressor gene and is supported by findings
that show localisation of ERb to chromosome 14q is
shared by other tumour suppressor genes that exert pro-
tective effects in prostate and ovarian cancer [61]. Regres-
sion of tumours and improved survival may be achieved
by inhibition of cell proliferation as discussed or alterna-
tively by increased apoptosis as has been observed in pros-
tate cancer. Apoptosis involves a series of cellular events
involving loss of membrane gradients, DNA fragmentation
and caspase activity. In cancers, such as malignant
mesothelioma [62], ERb appears to be proapoptotic thus
enabling it to destroy malignant cells whilst ERa has antia-
poptotic activity which underpins its role in normal and
abnormal cell proliferation.
Epigenetic modifications
Tumourigenesis may be triggered by epigenetic changes
that involve modifications to chromatin structure
including DNA methylation and altered histone acetyla-
tion thus causing downstream changes in gene expres-
sion [66]. Studies in prostate and breast cancer [67]
have demonstrated hypermethylation of the ERb promo-
ter with subsequent silencing of ERb expression but no
evidence yet exists for altered ER methylation in oeso-
phageal cancer.
Circulating oestrogen levels
In premenopausal women, ovarian E2 levels are high,
largely attributable to the aromatisation of testosterone
to oestradiol-17b within the ovary. For postmenopausal
women in whom ovarian E2 levels are reduced, oestrone
is the most abundant oestrogen formed from its precur-
sor, androstenedione. Peripheral aromatization of oes-
t r o n ef r o ma n d r o g e n si na d i p o s et i s s u ei so n e
mechanism whereby circulating oestrogen levels may be
increased, perhaps explaining in part the gender selectiv-
ity of oesophageal cancer. Although it is unlikely, that
oestrogen levels will rise to those present in premeno-
pausal women, given the lower affinity of oestrone for
ERa, oestrone may still have the capability to confer
oestrogenic effects but with less potency. To date, it is
not known whether aromatase is produced by the oeso-
phagus but if it is, then it may be factors such as the
ratio of local oestrogen to androgen production as well
as the form of oestrogen produced (oestrone, oestradiol,
oestriol) that may underlie gender bias and the
increased risk of postmenopausal women and males to
oesophageal cancer compared with their premenopausal
females. More scientifically robust studies as proposed
by Hogan et al., are needed [68].
Therapeutic relevance of ERs to oesophageal
cancer
Therapeutic modalities currently in place for modulation
of ER activity include selective oestrogen receptor mod-
ulators (SERMs) e.g. tamoxifen which exhibits oestro-
genic activity depending upon the target tissue.
Tamoxifen, acts as an agonist in bone and the cardio-
vascular system in postmenopausal women but as an
antagonist in the breast of premenopausal women where
it has revolutionized breast cancer treatment in the form
of adjuvant endocrine therapy [69]. In the same way,
another popular SERM, raloxifene is used in osteoporo-
sis to improve bone mineral density where it exhibits
greater agonist activity [69]. The variation in the
response of a particular SERM either as an agonist or
antagonist depends on several factors. Thus, once a
SERM attaches to the ER, a specific conformational
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which corepressors and/or coactivators are recruited to
the promoter. Based upon these factors, tamoxifen
recruits a coactivator complex to oestrogen regulated
genes in endometrial cells whilst it recruits a corepres-
sor complex to the same gene in breast cancer cells
[70]. There is a paucity of information in relation to the
role of phytooestrogens, albeit of lower potency at the
ER but, appear to exhibit greater selectivity for ERb over
ERa [71] An effect of environmental oestrogens and
ERs in the pathogenesis of oesophageal cancer has not
been reported to date but may introduce another level
of complexity in the contribution of ER in the aetiology
of this disease.
Potential for future research
Most patients with oesophageal cancer present late with
inoperable disease. Despite recent advancement in surgi-
cal and oncological treatment, the five year survival after
oesophagectomy is about 25% [72,73] hence new means
of predicting disease onset and treating oesophageal
cancer in order to improve outcomes need to be
explored. From the limited number of investigations
reported for ER expression in oesophageal cancer, the
varied experimental design of these studies, different
antibodies used and few other techniques to confirm
these findings, it is too early to draw definitive conclu-
sions regarding the future therapeutic utility of ERs in
oesophageal cancer. However, evidence presented herein
indicates that the presence of ERs appears to have
greater significance than other sex steroid receptors
while three studies report relatively raised ERb expres-
sion with oesophageal tumour dedifferentiation.
Although we are some considerable way off from under-
standing the apparent paradox of increased ER expres-
sion in oesophageal cancer and a seemingly better
prognosis in women, a concerted research effort is
required in order to determine relative levels of ERa:
ERb according to gender and age, ER expression pat-
terns with disease progression, modulation of oestrogen
production and the role of environmental and phytooes-
trogens, by immunochemical, molecular and functional
assays. The use of powerful experimental techniques
such as gene microarrays, chromatin immunoprecipita-
tion to investigate transcriptional regulation of ER and
silencing of ER subtypes using siRNA methods to tease
apart the complexity of the disease process will provide
us with deeper insight into underlying mechanisms at
play.
Although the two histological subtypes AC and SCC,
vary in their origin, aetiology and incidence, the strong
male predominance of oesophageal cancer highlights the
importance of further investigation regarding oestrogen
receptors and ER pathways, as also agreed by a recently
published review by Chandanos et al [74]. If conclusive
evidence of a role for oestrogen and its receptors s
obtained, then this paves the way for the development
of a new diagnostic biomarker in early diagnosis and
treatment of this disease. Published studies provide only
a hint of the possible use of sex hormone therapy for
managing oesophageal cancer. Nonetheless, if a role for
ERs in oesophageal cancer is proven this could poten-
tially lead to new and revolutionary approaches in the
form of hormonal therapy to treat oesophageal cancer.
Search strategy and selection criteria
Information for this personal review was obtained by
searches between March 1978 to October 2009 of
Pubmed using the following key words: ‘oestrogen
receptors’, ‘sex hormones’, ‘oesophageal cancer’ and ‘oes-
trogen’. Papers or abstracts published in English were
included. All authors reviewed original articles and
reviews for relevance and included all pertinent studies
in the preparation of the manuscript. We have also con-
sidered the bibliographies of the selected articles for the
pertinent citations.
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